© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
Andrew J. Cutler, MD, and Rakesh Jain, MD, MPH, discuss current and emerging therapies for the management of attention deficit hyperactivity disorders (ADHD).
March 12th 2021
Andrew J. Cutler, MD, provides an overview of the different presentations of attention deficit hyperactivity disorders (ADHD) and the clinical burden on children and adults.
Rakesh Jain, MD, MPH, comments on factors pre-disposing children and adults to ADHD and the impact of disease on patients’ and caregivers’ quality of life (QoL).
March 19th 2021
Updates in the AAP (American Academy of Pediatrics) and SDBP (Society for Developmental and Behavioral Pediatrics) guidelines for the assessment, evaluation, and treatment of ADHD in children and adolescents.
A review of common signs and symptoms prompting testing for ADHD and approaching ADHD diagnosis in adults.
Andrew J. Cutler, MD, and Rakesh Jain, MD, MPH, comment on comorbid psychiatric disorders complicating the diagnostic process for ADHD and review unmet needs.
Andrew J. Cutler, MD, discusses the benefits of cognitive behavior therapy (CBT), exercise, and family therapy for the management of ADHD.
Rakesh Jain, MD, MPH, shares his thoughts on the importance of combining pharmacological and non-pharmacological treatments for the management of ADHD.
Andrew J. Cutler, MD, reviews currently available stimulants and nonstimulants as well as their safety and efficacy for the treatment of ADHD.
Rakesh Jain, MD, MPH, considers the evidence-based recommended hierarchy in the choice of medications for the treatment of pediatric and adult ADHD.
A discussion on the recent development of investigational serotonin norepinephrine modulating agent (SNMA), SPN-812, for the treatment of ADHD in adults.